A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye

This study has been completed.

First Received: November 9, 2006 Last Updated: August 17, 2007 History of Changes

Sponsored by:	Innovative Medical
Information provided by:	Innovative Medical
ClinicalTrials.gov Identifier:	NCT00399230

Purpose

To evaluate the effectiveness of NGT (Optive) vs. Systane Tears for patients with moderate to severe dry eye disease.

Condition	Intervention	Phase
Dry Eye	Drug: Optive	Phase IV

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Active Control, Single Group Assignment

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Exclusion Criteria:

· Concurrent enrollment in an investigational drug or device study, or participation in such a study within 30 days of entry into this study.
- Subject has a condition, or is in a situation which, in the investigator's opinion, may put the subject at a significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00399230

Locations

United States, Virginia
Dr. Rajpal
McLean, Virginia, United States, 22102

Sponsors and Collaborators

Innovative Medical

Investigators

Principal Investigator:

Rajesh Rajpal, MD

See Clearly Vision Group

More Information

No publications provided

Study ID Numbers:	5279
Study First Received:	November 9, 2006
Last Updated:	August 17, 2007
ClinicalTrials.gov Identifier:	NCT00399230 History of Changes
Health Authority:	United States: Institutional Review Board

ClinicalTrials.gov processed this record on September 11, 2009